The tweet was deleted by the author.
But we saved everything 🙂.
Arcus Biosciences announced that data from its ARC-20 platform study are now published in Nature.
The kidney cancer study is described as the first to comprehensively explore the connection between tumor biology, a biomarker, and clinical activity for a HIF-2α inhibitor. Further details are available through the company’s provided link.
View post on X Loading...
RCUS remains firmly above its key averages, with the current price of $30.08 trading well above the MA-20 ($25.80), MA-50 ($25.16), and MA-200 ($21.58). This alignment underscores strong short-, medium-, and long-term bullish momentum; the Ichimoku Kijun at $26.79 marks immediate support below the current price. The nearest support is clustered around the Kijun ($26.79) and MA-20 ($25.80), while MA-50 ($25.16) provides an additional cushion as key support. Resistance is closest at MA-5 ($30.39), with the next key level being the recent high at $31.32.
Momentum on D1 is moderately bullish, with MACD pointing to continued buyer interest but ADX at 17.28 suggesting trend strength is subdued. Oscillator readings are stretched: RSI signals a "Buy" at 73.28, and CCI and Stoch RSI are both overbought, raising caution for short-term pullbacks. BBP indicates buyers still dominate, though the HMA signals a possible loss of momentum, and the AO remains bullish. RCUS is trading at $30.08, down from the previous week’s close of $31.00, showing a 4.03% decline; the price is currently in the middle of the weekly range as volatility reaches 13.36%. Overall, the tone this week reflects a steady pullback from recent highs after a rapid climb, with momentum signals and oscillator warnings diverging.
For the coming week, the expected trading range is $29.64 to $30.82, close to the current price and representing consolidation well above the 52-week low ($8.03) but near the annual high ($31.74). The probability of a price increase is very high (more than 80%), based on all major W1 signals (RSI, ADX, MACD, and MA-50) aligning bullish, making further declines much less likely. The baseline scenario sees RCUS holding within the $29.64–$30.82 band as momentum digests prior gains. A bullish breakout above $30.82 could retest the yearly high, while a bearish turn below $29.64 might trigger a retreat toward the lower band of near-term supports.
Earlier, analysts noted that Arcus Biosciences maintained a bullish medium- to long-term outlook despite near-term volatility and seller pressure. In light of recent developments, traders should pay close attention to shifts in momentum that could redefine the prevailing scenario for RCUS.